Category: Montana Bioscience Enterprises in the News

Wintermute Biomedical has successfully raised USD 1.3 million from investors to propel its groundbreaking Shingles treatment, Solexan™, into a Phase Ib clinical trial. The primary focus of this randomized double-blind placebo-controlled trial is to assess the safety, tolerability, and proof-of-concept efficacy of Solexan™ in reducing shingles-related pain and expediting lesion healing.

Golden Helix, Inc. announced that it has received the certification for ISO 13485:2016 from TÜV SÜD. ISO 13485:2016 is an international standard that specifies requirements for a quality management system (QMS) for organizations involved in the design, development, production, and servicing of medical devices. 

Golden Helix, Inc. announced that it has received the certification for ISO 13485:2016 from TÜV SÜD. ISO 13485:2016 is an international standard that specifies requirements for a quality management system (QMS) for organizations involved in the design, development, production, and servicing of medical devices. It is specifically tailored to the medical device industry and is recognized globally as a benchmark for ensuring the quality and safety of medical devices.

The National Institutes of Health recently awarded a Montana State University doctoral student a prestigious Graduate Partnership Program Fellowship. Through the fellowship, Jonathan Shikany, a second-year doctoral student in MSU’s Department of Chemical and Biological Engineering in the Norm Asbjornson College of Engineering, will receive funding for tuition and living expenses as he completes his degree, as well as funding to cover research-related expenses.  

The grant money will launch the Center for Integrated Biomedical and Rural Health Research or CIB-RHR, expanding the research enterprise over the next five years, with the ultimate hope of bringing healthcare improvements to the state.

Sana Health and Lutroo Imaging emerged victorious among 70 competing startups and early-stage companies, securing the top honors at the inaugural American Academy of Pain Medicine (AAPM) and MIT Hacking Medicine Innovation Challenge presented by Abbott. Their success grants them the coveted opportunity to collaborate with Michael Hooten, M.D., president of AAPM and professor of Anesthesiology at the Mayo Clinic.

The Montana Innovation Partnership at Montana State University’s TechLink Center will host “Innovate Here,” a one-day virtual conference March 7 focused on key technology industries in Montana, such as bioscience, photonics and quantum technologies.  

Microbion recently announced another significant milestone in the development of its lead drug candidate, pravibismane. The U.S. FDA has granted pravibismane a second orphan drug designation for the treatment of non-tuberculous mycobacterial (NTM) infections.

In a recent dissertation by Carlos Jaser Lara de Larrea, the focus turns to practical solutions for a cleaner water future. The research, titled “Treatment of biofilms and opportunistic pathogens in simulated drinking water distribution systems using UV LEDs,” takes a straightforward approach to tackle biofilm issues in drinking water systems.

This revolutionary new immunotherapy will combine Intrommune’s disease-modifying treatment through its peanut oral mucosal immunotherapy (OMIT), with the rapid desensitization to allergens provided by Inimmune’s clinical stage proprietary immunotherapy.